IL1B and AL amyloidosis: Whereas the bulk of the evidence point to IL-1β as the main driver of inflammasome tumor-promoting effects, a recent study by Hofbauer et al., studying multiple myeloma in a murine model, described a role of Nlrp3-dependent IL-18 in bone destruction and multiple myeloma proliferation (Hofbauer et al., 2021).